Search This Blog

Tuesday, March 17, 2026

X4 gets EMA CHMP positive opinion backing EU approval of mavorixafor for WHIM syndrome

 

X4 Pharmaceuticals gets EMA CHMP positive opinion backing EU approval of mavorixafor for WHIM syndrome

  • Reported fiscal Q4 2025 non-GAAP EPS of $-0.22, a 96% YoY improvement, beating analyst estimates
  • Fiscal Q4 2025 revenue was $2.6M, up 79% YoY, also ahead of revenue estimates
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)